Clinical Starter Packs

Curated starting points for high-yield specialties

Each pack brings together a key guideline, a current trial, a Drug Science explainer, and a relevant education item so clinicians can get oriented fast.

6 specialties 4 content pillars per pack Open clinical learning

Starter Packs

Use these as orientation pages for a topic area, then continue into the full specialty hub, Trial Radar, Drug Science and education library.

Diabetes / Metabolic

Key Guideline

Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes

Teplizumab is recommended for people aged 8 years and over with stage 2 type 1 diabetes to delay progression to…

View guideline →

Trial Radar

Effects of Quercetin on Cardiometabolic Outcomes

Quercetin supplement compared to placebo in randomized trial to test whether it improves heart disease and diabetes risk factors.

View trial →

Drug Science

HMG-CoA Reductase — Statins

HMG-CoA Reductase — Statins is a clinically relevant Drug Science explainer.

Open explainer →

Education

NICE NG28: Type 2 Diabetes in Adults — 2024 Update

Apply NICE NG28 updates to type 2 diabetes treatment sequencing, including when SGLT2 inhibitors or GLP-1 receptor agonists should be…

Start learning →

📰

Latest Clinical Brief Weekly type 2 diabetes jab could replace daily injections

Explore specialty hub Follow this specialty

Cardiology / Cardiovascular

Key Guideline

Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction

Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can…

View guideline →

Trial Radar

Mechanisms of Atrial Pathoelectrophysiology in HCM

This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder…

View trial →

Drug Science

HMG-CoA Reductase — Statins

HMG-CoA Reductase — Statins is a clinically relevant Drug Science explainer.

Open explainer →

Education

Cardiovascular Risk Reduction — Latest Evidence 2024

Use QRISK3 and clinical risk factors to identify patients who need lipid-lowering intensification.

Start learning →

📰

Latest Clinical Brief Campaigners hold vigil as stroke unit closes

Explore specialty hub Follow this specialty

Respiratory / COPD / Asthma

Key Guideline

Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over (terminated evaluation)

Evaluation terminated: Brensocatib for non-CF bronchiectasis is no longer under NICE appraisal—do not initiate new treatment pathways for this indication…

View guideline →

Trial Radar

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer’s Disease

This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology…

View trial →

Drug Science

CFTR Modulation

CFTR Modulation is a clinically relevant Drug Science explainer.

Open explainer →

Education

NICE NG185: COVID-19 Rapid Guideline — Long-term Effects

Distinguish ongoing symptomatic COVID-19 from post-COVID-19 syndrome using NICE NG185 definitions.

Start learning →

📰

Latest Clinical Brief Only around half of primary school children got their flu vaccine last year

Explore specialty hub Follow this specialty

Oncology

Key Guideline

Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer

Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition…

View guideline →

Trial Radar

International Prospective REgistry on Pre-pectorAl Breast REconstruction

This is an international multicenter prospective cohort study aimed at collecting data on breast reconstruction techniques with pre-pectoral implants after…

View trial →

Drug Science

BRAF/MEK Pathway — Melanoma

BRAF/MEK Pathway — Melanoma is a clinically relevant Drug Science explainer.

Open explainer →

Education

Coming into focus

We’re still building this layer for Oncology.

📰

Latest Clinical Brief ‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times

Explore specialty hub Follow this specialty

Rheumatology

Key Guideline

Osteoporosis: risk assessment

Use the FRAX tool or DXA scan results to stratify fracture risk in adults aged 50+ with risk factors (prior…

View guideline →

Trial Radar

Development of a New Patient Reported Outcome Measure (PROM) to Assess Patient’s Emotional Wellbeing, and Perceptions of Total Knee Replacement Surgery for the Treatment of Knee Arthritis

Researchers created a new questionnaire to measure how knee replacement patients feel emotionally and perceive their surgery outcomes.

View trial →

Drug Science

IL-6 Signalling

IL-6 Signalling is a clinically relevant Drug Science explainer.

Open explainer →

Education

JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance

Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease.

Watch webinar →

📰

Latest Clinical Brief ‘I’ve never been this good’ – revolutionary immune reset puts lupus in remission

Explore specialty hub Follow this specialty

Infectious Disease

Key Guideline

Transvenous embolisation for spontaneous intracranial hypotension caused by a cerebrospinal fluid–venous fistula

Consider transvenous embolisation in patients with spontaneous intracranial hypotension confirmed to have a cerebrospinal fluid–venous fistula, as it offers a…

View guideline →

Trial Radar